Therapeutic Advances in Medical Oncology
@tamedoncol.bsky.social
A SAGE Publishing Gold #openaccess journal | Publishing innovative clinically focused articles on the medical treatment of cancer| PubMed Indexed | IF: 4.2
Review on pregnancy & breast cancer in young women: PrBC vs PPBC distinctions, chemo during pregnancy (incl. taxanes after 1st trimester), POSITIVE trial on ET interruption, and fertility preservation gaps for targeted agents.
🔗 buff.ly/ZDZelh2
#BreastCancer #YWBC
🔗 buff.ly/ZDZelh2
#BreastCancer #YWBC
February 7, 2026 at 6:03 PM
Review on pregnancy & breast cancer in young women: PrBC vs PPBC distinctions, chemo during pregnancy (incl. taxanes after 1st trimester), POSITIVE trial on ET interruption, and fertility preservation gaps for targeted agents.
🔗 buff.ly/ZDZelh2
#BreastCancer #YWBC
🔗 buff.ly/ZDZelh2
#BreastCancer #YWBC
Review: Histologic transformation is a key mechanism of resistance in driver‑positive NSCLC, leading to aggressive SCLC, squamous, or neuroendocrine phenotypes.⬇️ summarize mechanisms and treatment options.
🔗 buff.ly/jJq7xOQ
#NSCLC #LungCancer #Oncology #TargetedTherapy
🔗 buff.ly/jJq7xOQ
#NSCLC #LungCancer #Oncology #TargetedTherapy
February 4, 2026 at 6:04 PM
Review: Histologic transformation is a key mechanism of resistance in driver‑positive NSCLC, leading to aggressive SCLC, squamous, or neuroendocrine phenotypes.⬇️ summarize mechanisms and treatment options.
🔗 buff.ly/jJq7xOQ
#NSCLC #LungCancer #Oncology #TargetedTherapy
🔗 buff.ly/jJq7xOQ
#NSCLC #LungCancer #Oncology #TargetedTherapy
A Phase IV real‑world analysis examined fruquintinib safety in two under‑studied CRC populations in China: young adults (<50) and the late‑elderly (≥75). Safety events were comparable between age groups, supporting broad applicability.
buff.ly/1Wpdefh
#ColorectalCancer
buff.ly/1Wpdefh
#ColorectalCancer
February 2, 2026 at 2:18 AM
A Phase IV real‑world analysis examined fruquintinib safety in two under‑studied CRC populations in China: young adults (<50) and the late‑elderly (≥75). Safety events were comparable between age groups, supporting broad applicability.
buff.ly/1Wpdefh
#ColorectalCancer
buff.ly/1Wpdefh
#ColorectalCancer
New real‑world evidence on Utidelone (UTD1) for mBC
In a multicenter retrospective study of 270 pts, UTD1, used mainly in combination regimens, showed encouraging effectiveness in heavily pretreated populations.
Link: buff.ly/nayTcuy
#BreastCancer #MBC #Oncology
In a multicenter retrospective study of 270 pts, UTD1, used mainly in combination regimens, showed encouraging effectiveness in heavily pretreated populations.
Link: buff.ly/nayTcuy
#BreastCancer #MBC #Oncology
January 28, 2026 at 4:00 PM
New real‑world evidence on Utidelone (UTD1) for mBC
In a multicenter retrospective study of 270 pts, UTD1, used mainly in combination regimens, showed encouraging effectiveness in heavily pretreated populations.
Link: buff.ly/nayTcuy
#BreastCancer #MBC #Oncology
In a multicenter retrospective study of 270 pts, UTD1, used mainly in combination regimens, showed encouraging effectiveness in heavily pretreated populations.
Link: buff.ly/nayTcuy
#BreastCancer #MBC #Oncology
Doublet vs triplet chemo in advanced gastric & GEJ cancer: which wins?
Multi-center study (493 pts) compared mFOLFOX-6 vs mDCF.
Results: Similar efficacy (ORR ~37%, PFS 6 - 7 mo, OS ~12 mo), but mFOLFOX-6 had fewer grade 3-4 hematologic toxicities.
🔗https://buff.ly/UvoGGkJ
Multi-center study (493 pts) compared mFOLFOX-6 vs mDCF.
Results: Similar efficacy (ORR ~37%, PFS 6 - 7 mo, OS ~12 mo), but mFOLFOX-6 had fewer grade 3-4 hematologic toxicities.
🔗https://buff.ly/UvoGGkJ
January 23, 2026 at 8:15 AM
Doublet vs triplet chemo in advanced gastric & GEJ cancer: which wins?
Multi-center study (493 pts) compared mFOLFOX-6 vs mDCF.
Results: Similar efficacy (ORR ~37%, PFS 6 - 7 mo, OS ~12 mo), but mFOLFOX-6 had fewer grade 3-4 hematologic toxicities.
🔗https://buff.ly/UvoGGkJ
Multi-center study (493 pts) compared mFOLFOX-6 vs mDCF.
Results: Similar efficacy (ORR ~37%, PFS 6 - 7 mo, OS ~12 mo), but mFOLFOX-6 had fewer grade 3-4 hematologic toxicities.
🔗https://buff.ly/UvoGGkJ
Can carboplatin AUC10 replace cisplatin in metastatic good-risk seminoma? Updated multi-centre study (236 pts, 21 yrs) shows 5-year PFS 89%, OS 93% with carboplatin AUC10.
Elevated LDH predicts worse outcomes, but survival remains comparable.
🔗 buff.ly/3bOeiMh
Elevated LDH predicts worse outcomes, but survival remains comparable.
🔗 buff.ly/3bOeiMh
January 21, 2026 at 8:15 AM
Can carboplatin AUC10 replace cisplatin in metastatic good-risk seminoma? Updated multi-centre study (236 pts, 21 yrs) shows 5-year PFS 89%, OS 93% with carboplatin AUC10.
Elevated LDH predicts worse outcomes, but survival remains comparable.
🔗 buff.ly/3bOeiMh
Elevated LDH predicts worse outcomes, but survival remains comparable.
🔗 buff.ly/3bOeiMh
How deep should PSA go in mCSPC?
⬇️ finds that achieving PSA ≤0.02 ng/mL within 6 months predicts significantly longer rPFS. Could this ultra-low threshold guide future trial design?
🔗 buff.ly/zGZ7FfA
#ProstateCancer #Oncology #mCSPC #PSA #CancerResearch
⬇️ finds that achieving PSA ≤0.02 ng/mL within 6 months predicts significantly longer rPFS. Could this ultra-low threshold guide future trial design?
🔗 buff.ly/zGZ7FfA
#ProstateCancer #Oncology #mCSPC #PSA #CancerResearch
January 19, 2026 at 8:15 AM
How deep should PSA go in mCSPC?
⬇️ finds that achieving PSA ≤0.02 ng/mL within 6 months predicts significantly longer rPFS. Could this ultra-low threshold guide future trial design?
🔗 buff.ly/zGZ7FfA
#ProstateCancer #Oncology #mCSPC #PSA #CancerResearch
⬇️ finds that achieving PSA ≤0.02 ng/mL within 6 months predicts significantly longer rPFS. Could this ultra-low threshold guide future trial design?
🔗 buff.ly/zGZ7FfA
#ProstateCancer #Oncology #mCSPC #PSA #CancerResearch
NSCLC remains the leading cause of cancer mortality. This review explores how IO is being integrated into neoadjuvant, perioperative & adjuvant settings to reduce recurrence and improve survival.
👉https://buff.ly/ZsztUQH
👉https://buff.ly/ZsztUQH
January 16, 2026 at 8:15 AM
NSCLC remains the leading cause of cancer mortality. This review explores how IO is being integrated into neoadjuvant, perioperative & adjuvant settings to reduce recurrence and improve survival.
👉https://buff.ly/ZsztUQH
👉https://buff.ly/ZsztUQH
🔍 Study on Tissue Factor (TF) in salivary gland carcinoma (SGC)!
SGC is a rare head & neck cancer with diverse molecular profiles. This study analyzed TF expression in 109 patients and its link to clinicopathological features.
👉 buff.ly/6E30XWj
SGC is a rare head & neck cancer with diverse molecular profiles. This study analyzed TF expression in 109 patients and its link to clinicopathological features.
👉 buff.ly/6E30XWj
January 14, 2026 at 8:15 AM
🔍 Study on Tissue Factor (TF) in salivary gland carcinoma (SGC)!
SGC is a rare head & neck cancer with diverse molecular profiles. This study analyzed TF expression in 109 patients and its link to clinicopathological features.
👉 buff.ly/6E30XWj
SGC is a rare head & neck cancer with diverse molecular profiles. This study analyzed TF expression in 109 patients and its link to clinicopathological features.
👉 buff.ly/6E30XWj
🔍 Review on HCC & lenvatinib response prediction!
HCC remains highly lethal, and while lenvatinib is a first-line option, not all patients benefit. This review explores biomarkers that predict response, aiming to guide personalized treatment.
👉https://buff.ly/xIRqZb2
HCC remains highly lethal, and while lenvatinib is a first-line option, not all patients benefit. This review explores biomarkers that predict response, aiming to guide personalized treatment.
👉https://buff.ly/xIRqZb2
January 12, 2026 at 8:15 AM
🔍 Review on HCC & lenvatinib response prediction!
HCC remains highly lethal, and while lenvatinib is a first-line option, not all patients benefit. This review explores biomarkers that predict response, aiming to guide personalized treatment.
👉https://buff.ly/xIRqZb2
HCC remains highly lethal, and while lenvatinib is a first-line option, not all patients benefit. This review explores biomarkers that predict response, aiming to guide personalized treatment.
👉https://buff.ly/xIRqZb2
Gut microbiome matters in lymphoma care! 🦠 It shapes responses to chemo, CAR-T, and stem cell transplant. Antibiotic use can disrupt this balance - future therapies may restore it.
🔗 Read more: buff.ly/pVU90WF
#Lymphoma #Microbiome #CancerResearch
🔗 Read more: buff.ly/pVU90WF
#Lymphoma #Microbiome #CancerResearch
January 9, 2026 at 8:01 AM
Gut microbiome matters in lymphoma care! 🦠 It shapes responses to chemo, CAR-T, and stem cell transplant. Antibiotic use can disrupt this balance - future therapies may restore it.
🔗 Read more: buff.ly/pVU90WF
#Lymphoma #Microbiome #CancerResearch
🔗 Read more: buff.ly/pVU90WF
#Lymphoma #Microbiome #CancerResearch
BMI and weight change ≠ survival predictors in mTNBC patients on sacituzumab govitecan. Real-world Polish data show no link to PFS, OS, or AEs.
🔗 Read more: buff.ly/kHtlvYH
#BreastCancer #mTNBC #Oncology
🔗 Read more: buff.ly/kHtlvYH
#BreastCancer #mTNBC #Oncology
January 7, 2026 at 8:15 AM
BMI and weight change ≠ survival predictors in mTNBC patients on sacituzumab govitecan. Real-world Polish data show no link to PFS, OS, or AEs.
🔗 Read more: buff.ly/kHtlvYH
#BreastCancer #mTNBC #Oncology
🔗 Read more: buff.ly/kHtlvYH
#BreastCancer #mTNBC #Oncology
TROP2 is almost universal in OSCC (96.5% positive; 84.1% moderate-high), while Nectin-4 appears in 38.8% - higher in HPV-positive cases. Promising ADC targets!
🔗 Read more: buff.ly/nH3QbYa
#HeadNeckCancer #TargetedTherapy #Oncology
🔗 Read more: buff.ly/nH3QbYa
#HeadNeckCancer #TargetedTherapy #Oncology
January 5, 2026 at 8:15 AM
TROP2 is almost universal in OSCC (96.5% positive; 84.1% moderate-high), while Nectin-4 appears in 38.8% - higher in HPV-positive cases. Promising ADC targets!
🔗 Read more: buff.ly/nH3QbYa
#HeadNeckCancer #TargetedTherapy #Oncology
🔗 Read more: buff.ly/nH3QbYa
#HeadNeckCancer #TargetedTherapy #Oncology
KRAS mutations matter! 🧬 In a cohort of 1667 advanced solid tumors, 28.1% had KRAS aberrations. G12D was most frequent (40.6%), and G12V/G13D linked to poor survival.
🔍 Learn more: buff.ly/Z7QSjPx
#Oncology #KRAS #CancerResearch
🔍 Learn more: buff.ly/Z7QSjPx
#Oncology #KRAS #CancerResearch
January 2, 2026 at 8:15 AM
KRAS mutations matter! 🧬 In a cohort of 1667 advanced solid tumors, 28.1% had KRAS aberrations. G12D was most frequent (40.6%), and G12V/G13D linked to poor survival.
🔍 Learn more: buff.ly/Z7QSjPx
#Oncology #KRAS #CancerResearch
🔍 Learn more: buff.ly/Z7QSjPx
#Oncology #KRAS #CancerResearch
Happy Holidays and a healthy New Year from Therapeutic Advances in Medical Oncology. Thank you to our authors, reviewers, EBMs, and readers for advancing cancer research in 2025 - we look forward to sharing more breakthroughs in 2026. #HappyNewYear #Oncology buff.ly/m1hvWDs
December 24, 2025 at 5:03 PM
Happy Holidays and a healthy New Year from Therapeutic Advances in Medical Oncology. Thank you to our authors, reviewers, EBMs, and readers for advancing cancer research in 2025 - we look forward to sharing more breakthroughs in 2026. #HappyNewYear #Oncology buff.ly/m1hvWDs
👵🧬 Gastric cancer is rising among elderly patients, posing unique treatment challenges. This review explores systemic therapy strategies, geriatric assessments, and emerging targeted options. Read more: buff.ly/H2tEtBs #Oncology #GastricCancer #GeriatricOncology
December 22, 2025 at 8:15 AM
👵🧬 Gastric cancer is rising among elderly patients, posing unique treatment challenges. This review explores systemic therapy strategies, geriatric assessments, and emerging targeted options. Read more: buff.ly/H2tEtBs #Oncology #GastricCancer #GeriatricOncology
A multicenter study of 33 advanced EC tumors treated with ICIs reveals:
MMRd/MSI‑H tumors show ~81% TLS/LA vs 17% in MMRp/MSS, with strong CD8–B cell interactions; Low stromal CD68⁺ TAM density strongly predicts ICI response (OR=11.7; AUC=0.75)
🔗 Read more: buff.ly/3GlHjtf
#EndometrialCancer
MMRd/MSI‑H tumors show ~81% TLS/LA vs 17% in MMRp/MSS, with strong CD8–B cell interactions; Low stromal CD68⁺ TAM density strongly predicts ICI response (OR=11.7; AUC=0.75)
🔗 Read more: buff.ly/3GlHjtf
#EndometrialCancer
December 19, 2025 at 8:15 AM
A multicenter study of 33 advanced EC tumors treated with ICIs reveals:
MMRd/MSI‑H tumors show ~81% TLS/LA vs 17% in MMRp/MSS, with strong CD8–B cell interactions; Low stromal CD68⁺ TAM density strongly predicts ICI response (OR=11.7; AUC=0.75)
🔗 Read more: buff.ly/3GlHjtf
#EndometrialCancer
MMRd/MSI‑H tumors show ~81% TLS/LA vs 17% in MMRp/MSS, with strong CD8–B cell interactions; Low stromal CD68⁺ TAM density strongly predicts ICI response (OR=11.7; AUC=0.75)
🔗 Read more: buff.ly/3GlHjtf
#EndometrialCancer
Capivasertib+Fulvestrant:a new targeted approach for HR⁺, HER2‑low/negative aBC, esp with PI3K/AKT/PTEN pathway alterations. Backed by FAKTION and Capitello 291, this combo shows strong efficacy and manageable safety. FDA approved 2023; NICE followed 2025.
🔗 Read more: buff.ly/yfdhSNi
#BreastCancer
🔗 Read more: buff.ly/yfdhSNi
#BreastCancer
December 17, 2025 at 8:15 AM
Capivasertib+Fulvestrant:a new targeted approach for HR⁺, HER2‑low/negative aBC, esp with PI3K/AKT/PTEN pathway alterations. Backed by FAKTION and Capitello 291, this combo shows strong efficacy and manageable safety. FDA approved 2023; NICE followed 2025.
🔗 Read more: buff.ly/yfdhSNi
#BreastCancer
🔗 Read more: buff.ly/yfdhSNi
#BreastCancer
Reposted by Therapeutic Advances in Medical Oncology
📣 All #ESMOImmuno25 congress sessions with speaker permission are now online for registered delegates & ESMO members on #OncologyPRO
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
December 16, 2025 at 4:30 PM
📣 All #ESMOImmuno25 congress sessions with speaker permission are now online for registered delegates & ESMO members on #OncologyPRO
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
Gastric-type endocervical adenocarcinoma is highly aggressive with poor prognosis. Immunoscore predicts survival, while Claudin 18.2 & PD-L1 offer potential therapeutic targets. #Oncology #CancerResearch
buff.ly/7K5gpdI
buff.ly/7K5gpdI
December 15, 2025 at 8:15 AM
Gastric-type endocervical adenocarcinoma is highly aggressive with poor prognosis. Immunoscore predicts survival, while Claudin 18.2 & PD-L1 offer potential therapeutic targets. #Oncology #CancerResearch
buff.ly/7K5gpdI
buff.ly/7K5gpdI
Menopause-related side effects are common in young women with HR+ early breast cancer on ovarian suppression + endocrine therapy. Hot flashes, night sweats, sleep issues & anxiety worsen over time, especially in women <40. Clinical care must address QoL. #BreastCancer
buff.ly/6mZJSAr
buff.ly/6mZJSAr
December 12, 2025 at 8:15 AM
Menopause-related side effects are common in young women with HR+ early breast cancer on ovarian suppression + endocrine therapy. Hot flashes, night sweats, sleep issues & anxiety worsen over time, especially in women <40. Clinical care must address QoL. #BreastCancer
buff.ly/6mZJSAr
buff.ly/6mZJSAr
ICI combos are reshaping hepatocellular carcinoma care. Phase III trials (IMbrave050, EMERALD-1, LEAP-012) show promise in resectable & embolization-eligible settings, but survival benefits remain unclear. More research is needed. #CancerResearch
🔗 Read the article: buff.ly/kbZ7ewQ
🔗 Read the article: buff.ly/kbZ7ewQ
December 10, 2025 at 8:15 AM
ICI combos are reshaping hepatocellular carcinoma care. Phase III trials (IMbrave050, EMERALD-1, LEAP-012) show promise in resectable & embolization-eligible settings, but survival benefits remain unclear. More research is needed. #CancerResearch
🔗 Read the article: buff.ly/kbZ7ewQ
🔗 Read the article: buff.ly/kbZ7ewQ
Immunotherapy is reshaping treatment for ES-SCLC. ICIs like atezolizumab & durvalumab push survival beyond 1 year. New targets & novel immune drugs may bring fresh hope.
buff.ly/IksCUnY
#CancerResearch #Immunotherapy
buff.ly/IksCUnY
#CancerResearch #Immunotherapy
December 8, 2025 at 8:15 AM
Immunotherapy is reshaping treatment for ES-SCLC. ICIs like atezolizumab & durvalumab push survival beyond 1 year. New targets & novel immune drugs may bring fresh hope.
buff.ly/IksCUnY
#CancerResearch #Immunotherapy
buff.ly/IksCUnY
#CancerResearch #Immunotherapy
EVs-exRNA in bladder cancer: progress, challenges & future prospects for clinical application. Read more buff.ly/WX2dUSP
#Oncology #PrecisionMedicine
#Oncology #PrecisionMedicine
December 5, 2025 at 8:15 AM
EVs-exRNA in bladder cancer: progress, challenges & future prospects for clinical application. Read more buff.ly/WX2dUSP
#Oncology #PrecisionMedicine
#Oncology #PrecisionMedicine
EBV-positive gastric cancer is not one disease - it’s six. New review maps six EBVaGC subtypes and links each to targeted therapies, from immune checkpoint inhibitors to lytic‑induction and PI3K/Akt strategies. Read the full review buff.ly/e6lgBX9 #Oncology #GastricCancer
December 4, 2025 at 8:35 AM
EBV-positive gastric cancer is not one disease - it’s six. New review maps six EBVaGC subtypes and links each to targeted therapies, from immune checkpoint inhibitors to lytic‑induction and PI3K/Akt strategies. Read the full review buff.ly/e6lgBX9 #Oncology #GastricCancer